tiprankstipranks
GRAIL Inc (GRAL)
NASDAQ:GRAL
US Market

GRAIL Inc (GRAL) Price & Analysis

Compare
124 Followers

GRAL Stock Chart & Stats


---

Bulls Say, Bears Say

Bulls Say
Financial StrategyCash preservation efforts are encouraging with Medicare reimbursement as a key catalyst to unlocking value.
Innovative TechnologyGRAL’s Galleri multi-cancer early detection screening test has the potential to address a significant unmet need.
Market OpportunityGRAIL is the pioneer in MCED testing, an exciting and large opportunity, if it works.
Bears Say
Financial ConcernsManagement is making early progress extending the cash runway with ~$850MM currently in hand, but there is potential for ~$400MM in annual burn, which is well above management targets.
Operational RisksA massive RIF cuts costs but also commercial heft, with potential margin impacting ASP pressures and a multi-year timeline to a potential FDA and CMS regulatory and reimbursement pathway raising concern.
Regulatory ChallengesThere are inherent risks associated with broadly commercializing novel technologies such as MCEDs, including an uncertain regulatory and reimbursement pathway.
---

Financials

Quarterly

Ownership Overview

28.55%12.27%0.93%49.71%
28.55% Insiders
0.93% Other Institutional Investors
49.71% Public Companies and Individual Investors

GRAL FAQ

What was GRAIL Inc’s price range in the past 12 months?
GRAIL Inc lowest stock price was $12.33 and its highest was $63.99 in the past 12 months.
    What is GRAIL Inc’s market cap?
    GRAIL Inc’s market cap is $1.58B.
      When is GRAIL Inc’s upcoming earnings report date?
      GRAIL Inc’s upcoming earnings report date is Feb 20, 2025 which is yesterday.
        How were GRAIL Inc’s earnings last quarter?
        GRAIL Inc released its earnings results on Feb 20, 2025. The company reported -$2.89 earnings per share for the quarter, beating the consensus estimate of -$4.973 by $2.083.
          Is GRAIL Inc overvalued?
          According to Wall Street analysts GRAIL Inc’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
            Does GRAIL Inc pay dividends?
            GRAIL Inc does not currently pay dividends.
            What is GRAIL Inc’s EPS estimate?
            GRAIL Inc’s EPS estimate is -4.97.
              How many shares outstanding does GRAIL Inc have?
              GRAIL Inc has 33,600,773 shares outstanding.
                What happened to GRAIL Inc’s price movement after its last earnings report?
                GRAIL Inc reported an EPS of -$2.89 in its last earnings report, beating expectations of -$4.973. Following the earnings report the stock price went same N/A.
                  Which hedge fund is a major shareholder of GRAIL Inc?
                  Currently, no hedge funds are holding shares in GRAL
                  ---

                  Company Description

                  GRAIL Inc

                  GRAIL is a healthcare company innovating to solve medicine's most important challenges. The Company's team of leading scientists, engineers and clinicians are on an urgent mission to detect cancer early, when it may be more treatable and potentially curable.
                  ---

                  GRAL Earnings Call

                  Q4 2025
                  0:00 / 0:00
                  Earnings Call Sentiment|Neutral
                  The earnings call reflected strong revenue growth and improved financial performance, driven by increased demand for the Galleri test. However, ongoing net losses and future revenue growth constraints due to lack of broad reimbursement temper the positive outlook. The company's strategic focus on FDA approval and reimbursement is critical for future scalability.Read More>
                  ---

                  GRAL Stock 12 Month Forecast

                  Average Price Target

                  $16.00
                  ▼(-69.58% Downside)
                  {"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"12":"$12","17":"$17","13.25":"$13.25","14.5":"$14.5","15.75":"$15.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":16,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$16.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":16,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$16.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":16,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$16.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[12,13.25,14.5,15.75,17],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2024","6":"Jun<br/>2024","9":"Sep<br/>2024","12":"Nov<br/>2024","25":"Nov<br/>2025"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,13.55,13.73846153846154,13.926923076923078,14.115384615384617,14.303846153846154,14.492307692307692,14.680769230769231,14.86923076923077,15.057692307692308,15.246153846153847,15.434615384615384,15.623076923076923,15.811538461538461,{"y":16,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,13.55,13.73846153846154,13.926923076923078,14.115384615384617,14.303846153846154,14.492307692307692,14.680769230769231,14.86923076923077,15.057692307692308,15.246153846153847,15.434615384615384,15.623076923076923,15.811538461538461,{"y":16,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,13.55,13.73846153846154,13.926923076923078,14.115384615384617,14.303846153846154,14.492307692307692,14.680769230769231,14.86923076923077,15.057692307692308,15.246153846153847,15.434615384615384,15.623076923076923,15.811538461538461,{"y":16,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":14.3,"date":1701388800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":14.3,"date":1704067200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":14.3,"date":1706745600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":14.3,"date":1709251200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":14.3,"date":1711929600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":14.3,"date":1714521600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":14.3,"date":1717200000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":14.96,"date":1719792000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":16.64,"date":1722470400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":14.11,"date":1725148800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":13.25,"date":1727740800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":13.25,"date":1727740800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":13.55,"date":1730419200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
                  Similar Stocks
                  Company
                  Price & Change
                  Follow
                  Exact Sciences
                  Illumina
                  Myriad Genetics
                  Natera
                  Guardant Health

                  Best Analysts Covering GRAL

                  1 Year
                  No data currently available
                  Popular Stocks
                  ---
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis